September 4, 2026
The industry spent two years bracing for roughly $6 billion in debt coming due by the end of 2026, with the five largest borrowers, all multi-state operators, carrying about $3.4 billion of it. Most of them got refinanced. The wall did not fall.
It moved to 2029 and 2030, and the price of moving it was a coupon in the low teens. That price is the story, because it is the number that decides what those companies can afford to spend for the next four years.
Curaleaf closed a $500 million private placement of 11.5% senior secured notes due February 18, 2029, in February 2026, and used it to redeem the $475 million of notes that would have matured on December 15 of this year. It was the largest note offering in the history of the U.S. cannabis industry.
Cresco Labs closed a $325 million senior secured term loan in August 2025 at 12.5%, maturing August 13, 2030, repaying a $360 million facility and cutting total debt in the process.
Trulieve took the other route. It redeemed all $368 million of its 8.0% notes with about $373 million of cash in December 2025, then issued $200 million of 10.5% notes due 2030, closing the second tranche on January 29.
Verano signed a $195 million senior secured term loan led by Needham Bank in March 2026, after upsizing its revolver to $100 million and pushing that maturity to February 2029.
Four companies, four deals, no defaults. On the maturity schedule this looks like a solved problem.
Run the arithmetic on those deals. Curaleaf's new notes cost about $57.5 million a year in interest. Cresco's term loan runs roughly $40.6 million. Trulieve's smaller stack costs about $21 million, on paper a bargain until you notice the rate went from 8.0% to 10.5% on the replacement paper.
Replacing 8% paper with 10.5% paper, as Trulieve did, is not deleveraging. It is buying time at a premium, and the premium is paid in cash every quarter out of the same operating income that was supposed to fund expansion once 280E relief arrived.
That is the trap in this year's earnings narrative. The tax change freed up real money. The refinancing wave claimed a large share of it before it reached a store buildout or a supplier's invoice.
Not everybody cleared the wall. AYR Wellness accumulated about $410 million in debt and ended up handing its Florida, New Jersey and Nevada operations to its own senior lenders through an Article 9 credit bid that closed June 2. TerrAscend's Michigan business went into receivership over $210 million owed to a single lender.
We covered where trade creditors land in those proceedings in who actually gets paid in a cannabis receivership. The short version has not changed: secured lenders first, everyone with an open invoice last.
The distinction between the two groups is access, not virtue. The MSOs with scale and clean collateral got 2029 and 2030 maturities at double-digit rates. The ones without got a receiver.
A company paying 11.5% on half a billion dollars treats working capital differently than one paying 8%. The effects show up in procurement long before they show up in a press release.
Payment terms stretch. Net 30 becomes net 45 becomes a conversation. Vendors get consolidated, because fewer suppliers means fewer invoices and better leverage on each one. Capital projects that were penciled in for 2027 get moved to 2028 without an announcement.
For anyone selling into these accounts, the read is straightforward. The large MSOs are stable enough to keep buying and stretched enough to negotiate hard, so price and terms matter more this cycle than they did last year. The single-state operators and small chains, which never had access to a $500 million placement, are where the credit risk actually sits.
Watch the refinancing dates in your accounts the way you watch renewal dates. A company that just repriced its whole capital structure has a fixed interest bill and a finance team that has been told to find it somewhere.
This is reporting on public filings and announcements, not investment advice.
How much cannabis debt matured in 2026? Roughly $6 billion across the industry, with about $3.4 billion of that concentrated in the five largest multi-state operators.
Did the MSOs refinance successfully? The largest ones did. Curaleaf, Cresco, Trulieve and Verano all extended maturities to 2029 or 2030 during 2025 and early 2026, at rates between 10.5% and 12.5%.
Why do the interest rates matter more than the maturity dates? Because the cash cost is permanent until the next refinancing. A rate that moves from 8% to 11.5% consumes operating income every quarter, which shapes capex, hiring and vendor payment terms.
Which operators are still at risk? Smaller and single-state operators without institutional collateral, plus companies already in restructuring. AYR Wellness and TerrAscend's Michigan business both ended up in lender-controlled processes rather than refinancings.
An account that just repriced its debt is a buyer with a tighter mandate and often a new person holding it. See verified, owner-level dispensary contacts across six states, refreshed weekly. There is a free preview at holdenleads.com.
Holden Leads
Holden Leads tracks every licensed dispensary across California, Michigan, Illinois, Massachusetts, New York, Colorado, Oregon, Washington, Nevada, and Maine — cross-referenced weekly against official state regulatory databases and enriched with phone numbers, emails, websites, and social profiles. Stop manually hunting for contact info. Get the full list today.